Effects of prostaglandin E1 (PGE1) on pulmonary hypertension and lung vascular remodeling in a rat monocrotaline model of human pulmonary hypertension

S. Ono, T. Tanita, Y. Hoshikawa, C. Song, S. Maeda, T. Tabata, M. Noda, S. Ueda, Y. Ashino, S. Fujimura

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Prostaglandin E1 (PGE1) has been shown to be a potent pulmonary vasodilator in humans and in many animals. The effects of PGE1 on the development of pulmonary hypertension and on pulmonary vascular remodeling were studied in a rat monocrotaline (MCT) model of human pulmonary hypertension. By 3 weeks after injection, MCT (80 mg/kg S.C.) had resulted in high values of mean pulmonary arterial pressure and of the ratio of right ventricular weight to left ventricle + septum weight (RV/LV + S). PGE1 inhibited the development of pulmonary hypertension (300 μg/kg) and right ventricular hypertrophy (300 and 100 μg/kg) induced by MCT. Three weeks after the injection, the media walls of pulmonary arteries in lungs from rats given MCT were significantly thicker than those from lungs of control rats. PGE, (300, 100, and 30 μg/kg) resulted in significantly less of this morphologic change, in a dose-dependent manner. These results indicate that PGE1 inhibits the development of pulmonary hypertension associated with lung vascular thickening induced by MCT. PGE1 may be useful for the treatment of pulmonary hypertension in humans.

Original languageEnglish
Pages (from-to)862-867
Number of pages6
JournalJapanese Journal of Thoracic Diseases
Volume33
Issue number8
Publication statusPublished - 01-01-1995
Externally publishedYes

Fingerprint

Monocrotaline
Alprostadil
Pulmonary Hypertension
Lung
Right Ventricular Hypertrophy
Weights and Measures
Injections
Prostaglandins E
Vasodilator Agents
Pulmonary Artery
Heart Ventricles
Blood Vessels
Vascular Remodeling
Arterial Pressure

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Cite this

Ono, S. ; Tanita, T. ; Hoshikawa, Y. ; Song, C. ; Maeda, S. ; Tabata, T. ; Noda, M. ; Ueda, S. ; Ashino, Y. ; Fujimura, S. / Effects of prostaglandin E1 (PGE1) on pulmonary hypertension and lung vascular remodeling in a rat monocrotaline model of human pulmonary hypertension. In: Japanese Journal of Thoracic Diseases. 1995 ; Vol. 33, No. 8. pp. 862-867.
@article{0a1d834fdd7e46e1affb3c916158780b,
title = "Effects of prostaglandin E1 (PGE1) on pulmonary hypertension and lung vascular remodeling in a rat monocrotaline model of human pulmonary hypertension",
abstract = "Prostaglandin E1 (PGE1) has been shown to be a potent pulmonary vasodilator in humans and in many animals. The effects of PGE1 on the development of pulmonary hypertension and on pulmonary vascular remodeling were studied in a rat monocrotaline (MCT) model of human pulmonary hypertension. By 3 weeks after injection, MCT (80 mg/kg S.C.) had resulted in high values of mean pulmonary arterial pressure and of the ratio of right ventricular weight to left ventricle + septum weight (RV/LV + S). PGE1 inhibited the development of pulmonary hypertension (300 μg/kg) and right ventricular hypertrophy (300 and 100 μg/kg) induced by MCT. Three weeks after the injection, the media walls of pulmonary arteries in lungs from rats given MCT were significantly thicker than those from lungs of control rats. PGE, (300, 100, and 30 μg/kg) resulted in significantly less of this morphologic change, in a dose-dependent manner. These results indicate that PGE1 inhibits the development of pulmonary hypertension associated with lung vascular thickening induced by MCT. PGE1 may be useful for the treatment of pulmonary hypertension in humans.",
author = "S. Ono and T. Tanita and Y. Hoshikawa and C. Song and S. Maeda and T. Tabata and M. Noda and S. Ueda and Y. Ashino and S. Fujimura",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "33",
pages = "862--867",
journal = "Respiratory Investigation",
issn = "2212-5345",
publisher = "Elsevier BV",
number = "8",

}

Effects of prostaglandin E1 (PGE1) on pulmonary hypertension and lung vascular remodeling in a rat monocrotaline model of human pulmonary hypertension. / Ono, S.; Tanita, T.; Hoshikawa, Y.; Song, C.; Maeda, S.; Tabata, T.; Noda, M.; Ueda, S.; Ashino, Y.; Fujimura, S.

In: Japanese Journal of Thoracic Diseases, Vol. 33, No. 8, 01.01.1995, p. 862-867.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of prostaglandin E1 (PGE1) on pulmonary hypertension and lung vascular remodeling in a rat monocrotaline model of human pulmonary hypertension

AU - Ono, S.

AU - Tanita, T.

AU - Hoshikawa, Y.

AU - Song, C.

AU - Maeda, S.

AU - Tabata, T.

AU - Noda, M.

AU - Ueda, S.

AU - Ashino, Y.

AU - Fujimura, S.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Prostaglandin E1 (PGE1) has been shown to be a potent pulmonary vasodilator in humans and in many animals. The effects of PGE1 on the development of pulmonary hypertension and on pulmonary vascular remodeling were studied in a rat monocrotaline (MCT) model of human pulmonary hypertension. By 3 weeks after injection, MCT (80 mg/kg S.C.) had resulted in high values of mean pulmonary arterial pressure and of the ratio of right ventricular weight to left ventricle + septum weight (RV/LV + S). PGE1 inhibited the development of pulmonary hypertension (300 μg/kg) and right ventricular hypertrophy (300 and 100 μg/kg) induced by MCT. Three weeks after the injection, the media walls of pulmonary arteries in lungs from rats given MCT were significantly thicker than those from lungs of control rats. PGE, (300, 100, and 30 μg/kg) resulted in significantly less of this morphologic change, in a dose-dependent manner. These results indicate that PGE1 inhibits the development of pulmonary hypertension associated with lung vascular thickening induced by MCT. PGE1 may be useful for the treatment of pulmonary hypertension in humans.

AB - Prostaglandin E1 (PGE1) has been shown to be a potent pulmonary vasodilator in humans and in many animals. The effects of PGE1 on the development of pulmonary hypertension and on pulmonary vascular remodeling were studied in a rat monocrotaline (MCT) model of human pulmonary hypertension. By 3 weeks after injection, MCT (80 mg/kg S.C.) had resulted in high values of mean pulmonary arterial pressure and of the ratio of right ventricular weight to left ventricle + septum weight (RV/LV + S). PGE1 inhibited the development of pulmonary hypertension (300 μg/kg) and right ventricular hypertrophy (300 and 100 μg/kg) induced by MCT. Three weeks after the injection, the media walls of pulmonary arteries in lungs from rats given MCT were significantly thicker than those from lungs of control rats. PGE, (300, 100, and 30 μg/kg) resulted in significantly less of this morphologic change, in a dose-dependent manner. These results indicate that PGE1 inhibits the development of pulmonary hypertension associated with lung vascular thickening induced by MCT. PGE1 may be useful for the treatment of pulmonary hypertension in humans.

UR - http://www.scopus.com/inward/record.url?scp=0029112840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029112840&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 862

EP - 867

JO - Respiratory Investigation

JF - Respiratory Investigation

SN - 2212-5345

IS - 8

ER -